Update on optimal use of omalizumab in management of asthma

Journal of Asthma and Allergy

Volumn 4, Issue , 2011, Pages 49-59

  Pelaia, Girolamo ^a,d   Gallelli, Luca ^a   Renda, Teresa ^a   Romeo, Pasquale ^a   Busceti, Maria Teresa ^a   Grembiale, Rosa Daniela ^a   Maselli, Rosario ^a   Marsico, Serafino Antonio ^b   Vatrella, Alessandro ^c  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d Campus Universitario S Venuta ^*  (Italy)

Author keywords

Anti IgE; Omalizumab; Severe asthma

Indexed keywords

ADENOSINE PHOSPHATE; ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; OMALIZUMAB; PLACEBO;

ADD ON THERAPY; ALLERGIC ASTHMA; ANAPHYLAXIS; ASTHMA; CARCINOGENESIS; CHURG STRAUSS SYNDROME; CLINICAL STUDY; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; DRUG USE; EMERGENCY CARE; FATIGUE; HELMINTHIASIS; HUMAN; IMMUNOREGULATION; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; INJECTION SITE URTICARIA; INJECTION SITE WARMTH; LUNG FUNCTION; MEDICAL PRACTICE; NAUSEA; PARASITOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PRESCRIPTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; TREATMENT DURATION;

EID: 84860701974     PISSN: 11786965     EISSN: None     Source Type: Journal    
DOI: 10.2147/JAA.S14520     Document Type: Review

References (82)